Compare AVXL & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | MTLS |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.1M | 296.8M |
| IPO Year | 2013 | 2014 |
| Metric | AVXL | MTLS |
|---|---|---|
| Price | $3.16 | $5.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 852.5K | 78.2K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.61 | $4.78 |
| 52 Week High | $13.99 | $6.80 |
| Indicator | AVXL | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 51.75 |
| Support Level | $2.93 | $4.93 |
| Resistance Level | $3.76 | $5.48 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 12.23 | 48.78 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.